Short Interest in Inogen, Inc. (NASDAQ:INGN) Increases By 8.8%

Inogen, Inc. (NASDAQ:INGN) was the target of a large increase in short interest during the month of January. As of January 31st, there was short interest totalling 798,600 shares, an increase of 8.8% from the January 15th total of 734,000 shares. Based on an average daily trading volume, of 224,800 shares, the days-to-cover ratio is currently 3.6 days.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the stock. JPMorgan Chase & Co. lifted its holdings in Inogen by 2.7% during the third quarter. JPMorgan Chase & Co. now owns 896,106 shares of the medical technology company’s stock worth $8,692,000 after acquiring an additional 23,891 shares during the period. Ameriprise Financial Inc. lifted its holdings in Inogen by 0.6% during the fourth quarter. Ameriprise Financial Inc. now owns 848,980 shares of the medical technology company’s stock worth $7,785,000 after acquiring an additional 5,148 shares during the period. Bridgeway Capital Management LLC lifted its holdings in Inogen by 4.7% during the fourth quarter. Bridgeway Capital Management LLC now owns 631,230 shares of the medical technology company’s stock worth $5,788,000 after acquiring an additional 28,517 shares during the period. Dimensional Fund Advisors LP lifted its holdings in Inogen by 25.4% during the fourth quarter. Dimensional Fund Advisors LP now owns 607,837 shares of the medical technology company’s stock worth $5,574,000 after acquiring an additional 123,208 shares during the period. Finally, Geode Capital Management LLC lifted its holdings in Inogen by 1.1% during the third quarter. Geode Capital Management LLC now owns 554,191 shares of the medical technology company’s stock worth $5,377,000 after acquiring an additional 5,921 shares during the period. Institutional investors own 89.94% of the company’s stock.

Wall Street Analyst Weigh In

INGN has been the subject of a number of analyst reports. StockNews.com upgraded Inogen from a “hold” rating to a “buy” rating in a research report on Monday, February 10th. Needham & Company LLC restated a “hold” rating on shares of Inogen in a research report on Thursday, January 30th.

Inogen Stock Performance

Shares of Inogen stock opened at $10.64 on Tuesday. Inogen has a 52 week low of $5.82 and a 52 week high of $13.33. The stock has a 50 day moving average price of $10.09 and a two-hundred day moving average price of $10.26. The stock has a market capitalization of $253.44 million, a PE ratio of -4.73 and a beta of 1.02.

Inogen Company Profile

Inogen, Inc, a medical technology company, develops, manufactures, and markets portable oxygen concentrators to patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.